雾化吸入干扰素α2b注射液治疗小儿呼吸道合胞病毒肺炎的疗效

目的 观察雾化吸入重组人干扰素α2b注射液治疗小儿呼吸道合胞病毒肺炎的疗效.方法 选择2013年9月至2014年8月保定市第一中心医院收治的60例呼吸道合胞病毒肺炎患儿,按照随机数字表法随机分为对照组和观察组,每组各30例.对照组患儿给予常规治疗,观察组患儿在常规治疗的基础上,雾化吸入干扰素α2b注射液10万IU/kg,1次/天.观察治疗1周后两组患儿咳嗽、喘憋、肺部啰音等症状消失的时间,血清肿瘤坏死因子-α(TNF-α)、白介素-10(IL-10)、白介素-18(IL-18)水平的变化以及不良反应发生例数.结果 治疗1周,观察组患儿咳嗽、喘憋及肺部啰音消失时间均短于对照组(4.11±0.89)d vs(5.19±1.27)、(4.01±1.17)d vs(5.22±1.35)d、(4.35±1.09)d vs(5.67±1.32)];观察组血清TNF-α、IL-18水平低于对照组(43.33±5.65)ng/L vs(58.27±6.21)ng/L、(176.39±88.31)ng/L vs(248.25±91.78)ng/L];IL-10水平高于对照组(19.74±6.88)ng/L vs(15.26±6.60)ng/L],差异均有统计学意义(P<0.05).观察组患儿治疗总有效率(96.42％)高于对照组(80.00％),差异有统计学意义(P<0.05),观察组不良反应发生率为6.67％,与对照组比较差异无统计学意义(P>0.05).结论 雾化吸入干扰素α2b注射液治疗小儿呼吸道合胞病毒肺炎能降低患者炎症因子水平,不良反应较轻,临床疗效显著.

Effect of spray inhalation with recombinant human interferon α2b injections on RSV pneumonia in children

Objective To observe the efficacy of spray inhalation with recombinant human interferonα2b injections in those children with respiratory syncytial viral ( RSV) pneumonia. Methods 60 patients with infantile RSV pneumonia ever treated in our hospital between Sep 2013 and Aug 2014 were collected, and then divided into the control group and the study group by means of random number table, 30 ca-ses in each group. Besides the conventional treatment given to the control group, children in the study group were given additional spray inha-lation with recombinant human interferonα2b injections, 100 thousand IU/kg for once a day. After treatment of one week, the recovery time from such symptoms as cough, dyspnea and lung rale in the two groups were recorded, and their serum levels of TNF-α, IL-10 and IL-18 were also detected. Results After treatment of one week, the recovery time from such symptoms as cough, dyspnea and lung rale in the study group were all much shorter than those in the control group (4. 11 ± 0. 89) d vs (5. 19 ± 1. 27) d; (4. 01 ± 1. 17) d vs (5. 22 ± 1. 35) d;(4. 35 ± 1. 09) d vs (5. 67 ± 1. 32) d], with significant differences between them (P<0. 05). The serum levels of TNF-αand IL-18 in the study group were significantly lower than those in the control group (43. 33 ± 5. 65) ng/L vs (58. 27 ± 6. 21) ng/L;(176. 39 ± 88. 31) ng/L vs (248. 25 ± 91. 78) ng/L], but the IL-10 level was significantly higher than that in the control group (19. 74 ± 6. 88) ng/L vs (15. 26 ± 6. 60) ng/L], and their differences were all statistically significant (P<0. 05). The total effective rate in the study group (96. 42％) was significantly higher than that in the control group (80. 00％; P<0. 05),the rate of adverse raction in the study group was 6. 67％,but no significant different between the control group and the study group(P>0. 05). Conclusion Administration of spray inhala-tion with recombinant human interferonα2b injections in treatment of patients with infantile RSV pneumonia could decrease their levels of in-flammatory factors, with mild adverse reactions and remarkable clinical efficacy.